IGI

We are excited to announce an exclusive licensing agreement with AbbVie to accelerate the development, manufacturing and commercialization of ISB 2001, IGI’s first-in-class trispecific T-cell engager for multiple myeloma and autoimmune diseases in North America, Europe, Japan and Greater China.   Built on our proprietary BEAT® platform and supported by promising early clinical data, ISB 2001 represents a new frontier in multispecifics™ antibody therapy.    Read the full announcement: https://bit.ly/4lOKkwY #IGI #AbbVie #Partnership #MultipleMyeloma #Immunology #BiotechCollaboration

At IGI, we believe breakthroughs happen when great minds collaborate. From whiteboard brainstorming to late-night trial readouts - our lab culture thrives on curiosity, rigor, and camaraderie.   #InsideIGI #InnovationCulture #IGInnovation 

At IGI, July 4 is a reminder of the values we live by – freedom to innovate, courage to challenge the status quo, and the relentless pursuit of breakthroughs in cancer care. From our headquarters in New York to clinical trials around the world, we salute the spirit of independence that drives science forward. Happy Independence Day! #Multispecifics #IGInnovation

Exciting new ISB 2001 data presented today at the Antibody Industrial Symposium by Cyrille Dreyfus, Associate Director, Head of Protein Sciences, IGI. Our bispecific approach continues to demonstrate potential across multiple tumor types. 📍 Tours, France | #AIS2025 #IGInnovation #AntibodyEngineering #NextGenBiologics

Excited to present clinical insights of our ISB 2001 data at #EHA2025 in Milan! Presented by Prof. Hang Quach, our latest data reflects IGI’s growing momentum in tackling hematologic cancers. #IGInnovation #EHA25 #NextGenBiologics

We are pleased to share the recent interview of our President and CEO, Cyril Konto, with OncoDaily, where he speaks about the vision, science, and strategy driving Ichnos Glenmark Innovation (IGI) forward. Read the full interview here: https://lnkd.in/eYg7kyTd #IGInnovation #OncoDaily #MultispecificsTM #ImmunoOncology

We are proud to share ISB 2001 data at AET Europe in Basel today, presented by Mario Perro, Head of Biologics Research, IGI. The data reinforce our commitment to bispecific innovation in hematologic malignancies. 📍 Basel, Switzerland #AETEurope #IGInnovation #ImmunoOncology #NextGenBiologics

We're excited to announce encouraging results from the full dose escalation of ISB 2001, a First-in-Class BCMA × CD38 × CD3 Trispecific Antibody, for the Treatment of Relapsed/Refractory Multiple Myeloma, presented at American Society of Clinical Oncology (ASCO). This milestone reinforces our commitment at IGI to advancing next-generation T-cell engagers in oncology. To read the full press release: https://lnkd.in/d-dNWW9x For detailed presentation, refer to: https://lnkd.in/d25fBUCU #OncologyInnovation #MultipleMyeloma #ImmunoOncology #IGInnovation #ASCO2025 #SciencetoStrategy

Join us at Booth #35131 at American Society of Clinical Oncology (ASCO), where we will showcase our latest progress in multispecificTM biologics for hematological malignancies and solid tumors. Meet our team, explore our pipeline, and discover how IGI is redefining oncology innovation. Let’s shape the future of cancer care, together. #Multispecifics #OncologyInnovation  #CancerResearch #ASCO25 #SciencetoStrategy

The countdown is almost over. At IGI, our focus is to push the boundaries of science to bring differentiated biologics to cancer patients. Join us at American Society of Clinical Oncology (ASCO) to explore our latest data and pipeline advancements, committed to transforming cancer care. #ASCO25 #ImmunoOncology #MutlispecificsTM #SciencetoStrategy